Completed the acquisition of Damora Therapeutics in November 2025, adding a pipeline of differentiated therapeutics targeting mutCALR-driven MPNs, including lead candidate DMR-001, and additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results